
SANARA MEDTECH INC
99
Recent developments include Sanara MedTech surpassing Q3 2026 earnings estimates, selling Tissue Health Plus assets, and receiving a Vizient Innovative Technology Contract for BIASURGE.
- Sanara MedTech Inc. surpassed Q3 2026 earnings estimates, indicating operational progress in its core surgical business [N1].
- The company sold Tissue Health Plus, LLC assets for approximately $2 million, reflecting the discontinuation of its post-acute wound care program [N1].
- Sanara MedTech received an Innovative Technology Contract from Vizient for its BIASURGE Advanced Surgical Solution, supporting commercial adoption [S1].
- Sanara MedTech topped Q2 2026 earnings estimates, demonstrating continued financial performance improvements [N5].
Sanara MedTech Inc. develops and commercializes surgical technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market. Its product offerings include soft tissue repair and bone fusion products designed for use in operating rooms and sterile environments. The company’s lead products include CellerateRX Surgical Powder, a hydrolyzed collagen aiding surgical wound management, and BIASURGE Advanced Surgical Solution, a sterile wound irrigation product with antimicrobial properties. Sanara MedTech has discontinued its Tissue Health Plus post-acute wound care program to focus exclusively on surgical products. The company maintains a research and development pipeline guided by the strategy 'Prepare, Promote and Protect' and has secured contracts with over 4,000 hospitals across the United States. It is currently undergoing a merger process with MiMedx, subject to regulatory approvals.
Sanara MedTech Inc. is a healthcare company specializing in surgical soft tissue repair and bone fusion products marketed primarily in the U.S. surgical market. The company has discontinued its post-acute value-based wound care program (Tissue Health Plus) and is focusing exclusively on surgical products. Its product portfolio includes clinically supported technologies such as CellerateRX Surgical and BIASURGE, which have demonstrated efficacy in improving wound healing and reducing complications. Sanara MedTech reported a net loss of approximately $1.41 million for Q3 2026 with a strong liquidity position as of September 30, 2026. The company is engaged in a pending merger with MiMedx, which faces regulatory review and associated risks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sanara MedTech’s clinical evidence-backed product portfolio addresses significant surgical challenges, potentially enabling improved patient outcomes and reduced healthcare costs. The company’s broad U.S. hospital network and focused commercial strategy support market penetration and geographic expansion. Its pipeline of innovative surgical products, including upcoming launches like OsStic BioAdhesive, may enhance its value proposition. The pending merger with MiMedx could provide strategic benefits if completed, and recent contract awards such as the Vizient Innovative Technology Contract for BIASURGE demonstrate market acceptance.
Risks include the uncertainty and potential delays related to the pending merger with MiMedx, which is subject to regulatory approvals and could adversely affect business operations and stock price if not completed. The discontinuation of the Tissue Health Plus program reflects challenges in diversifying beyond surgical products. The company reported a net loss in recent quarters, indicating ongoing profitability challenges. Market competition, regulatory hurdles, and potential attrition of key personnel amid merger uncertainty could impact execution and growth prospects.
Sanara MedTech’s moat is supported by its differentiated surgical technologies that address key surgical site complications and improve patient outcomes while reducing overall healthcare costs. The company’s products are backed by clinical and preclinical research demonstrating efficacy and safety, which supports adoption in surgical specialties. Its established commercial distribution network with contracts at thousands of hospitals and engagement with surgeons provides a scalable platform for growth. Additionally, the experienced leadership team and ongoing product innovation contribute to competitive positioning in the surgical medical instruments market.
• Merger Completion Risk: The pending merger with MiMedx is subject to regulatory approvals including a Second Request from the FTC, which may delay or prevent completion. Failure to complete the merger could negatively impact stock price and business operations [S2].
• Distraction and Operational Risks from Merger Process: Management attention and resources are devoted to the merger, potentially limiting pursuit of other business opportunities. The merger announcement may affect relationships with customers, suppliers, and employees [S2].
• Profitability and Financial Risks: The company reported a net loss of approximately $1.41 million for Q3 2026 and negative EPS in recent quarters, indicating ongoing challenges in achieving profitability [S2].
• Discontinuation of Post-Acute Care Program: The decision to discontinue the Tissue Health Plus value-based wound care program reflects challenges in that segment and a strategic refocus on surgical products [S1].
• Regulatory and Market Risks: Sanara MedTech operates in a competitive and regulated healthcare market where product adoption depends on clinical validation and reimbursement. Regulatory changes or competitive pressures could impact growth.
Business trends: Continued focus on surgical product innovation and expansion of U.S. hospital contracts; discontinuation of non-core post-acute wound care segment.
Execution milestones: Advancement of product pipeline including new product launches; completion of pending merger with MiMedx subject to regulatory approvals.
Key risks: Regulatory and completion risks related to the merger; ongoing profitability challenges; potential operational distractions and market competition.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market [S1].
- The company primarily markets and sells soft tissue repair and bone fusion products for use in operating rooms or sterile environments, including products like CellerateRX Surgical Powder, BIASURGE Advanced Surgical Solution, BiFORM Bioactive Moldable Matrix, and ALLOCYTE Plus Advanced Viable Bone Matrix [S1].
- Sanara MedTech had a value-based wound care services initiative called Tissue Health Plus (THP) which was discontinued in mid-September 2025 due to persistent losses and lack of investor interest; THP is now classified as discontinued operations [S1].
- The company has a research and development team (Rochal Technologies) advancing a pipeline of next-generation products guided by the strategy 'Prepare, Promote and Protect' [S1].
- Sanara MedTech has an exclusive license agreement with Tufts University for collagen peptide technology but is in the process of terminating this agreement to focus on surgical products [S1].
- The company’s mission includes delivering surgical solutions that improve patient outcomes, reduce complications, and lower overall healthcare costs, with a focus on the U.S. surgical tissue repair market [S1].
- Sanara MedTech’s commercial strategy includes expanding geographic footprint across the U.S. and deepening presence in surgical markets with a broad product portfolio [S1].
- The company has secured product contracts with more than 4,000 hospitals and engaged surgeons in key specialties across the United States as of end 2025 [S1].
- Preclinical and clinical research supports the efficacy and safety of key products such as CellerateRX Surgical and BIASURGE, including peer-reviewed studies demonstrating improved wound healing and reduced complications in various surgical specialties [S1].
- Sanara MedTech is led by an experienced senior leadership team with a multi-year track record in the surgical market [S1].
- The company reported net income loss of approximately $1.41 million for the quarter ended September 30, 2026, with cash and equivalents of about $16.8 million and a current ratio of 2.24 as of that date [S2].
- Earnings per share basic and diluted were both -$0.05 for the quarter ended June 30, 2026 [S2].
- Sanara MedTech has been involved in a pending merger with MiMedx, subject to regulatory approvals and conditions, including a Second Request from the FTC extending the waiting period [S2].
- The merger process has risks including potential delays, regulatory conditions, diversion of management attention, and possible adverse effects on business relationships and employee retention [S2].
- Recent news highlights include Sanara MedTech surpassing Q3 2026 earnings estimates and topping Q2 2026 earnings estimates, as well as selling Tissue Health Plus assets for approximately $2 million [N1][N5].
- The company has received an Innovative Technology Contract from Vizient for its BIASURGE Advanced Surgical Solution [S1].
- Sanara MedTech announced unaudited preliminary financial results for Q4 and full year 2025 and introduced full year 2026 financial guidance [S1].
Generated 2026-11-13
- S1 | 2026-03-24 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Sanara MedTech Inc. (SMTI) Surpasses Q3 Earnings Estimates | https://www.nasdaq.com/articles/sanara-medtech-inc-smti-surpasses-q3-earnings-estimates
- N2 | 2026-11-09 | www.nasdaq.com | Village Farms (VFF) Tops Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/village-farms-vff-tops-q3-earnings-and-revenue-estimates
- N3 | 2026-11-06 | www.nasdaq.com | Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/cresco-labs-inc-crlbf-reports-q3-loss-misses-revenue-estimates
- N4 | 2026-11-05 | www.nasdaq.com | Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/apyx-medical-apyx-reports-q3-loss-tops-revenue-estimates
- N5 | 2026-08-11 | www.nasdaq.com | Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates | https://www.nasdaq.com/articles/sanara-medtech-inc-smti-tops-q2-earnings-estimates
- N6 | 2026-08-06 | www.nasdaq.com | biote Corp. (BTMD) Reports Break-Even Earnings for Q2 | https://www.nasdaq.com/articles/biote-corp-btmd-reports-break-even-earnings-q2
- N7 | 2026-07-30 | www.nasdaq.com | Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up | https://www.nasdaq.com/articles/top-biotech-gainers-sprc-watch-avtr-neo-boost-full-year-outlook-smti-scooped
- N8 | 2026-06-02 | www.nasdaq.com | Sanara MedTech (SMTI) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/sanara-medtech-smti-q1-2026-earnings-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


